Colorectal Cancer Recurrent clinical trials

Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRD

Physical activity study for older cancer survivors with chronic pain

This study uses a smartphone program to encourage physical activity in older adults who have survived cancer and have ongoing pain. It aims to learn how to best help you move more and feel better.

Mindfulness program for couples facing metastatic colorectal cancer

This study tests a mindfulness-based program for couples facing metastatic colorectal cancer. It aims to help reduce distress and improve coping for both patients and their partners.

Early cancer detection test for colorectal cancer

This trial uses two blood tests (Signatera and Haystack) to look for tiny bits of cancer DNA after surgery, to find out if the cancer comes back as early as possible. People with stage II, III, or IV colorectal cancer who have had or will have surgery to remove their tumor may join.

Investigational drug plus bevacizumab for advanced colorectal cancer

This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.

Predicting polyp return after removal

This study aims to develop a tool using gut bacteria and metabolites to predict if high-risk colon polyps will come back after removal. If you are between 40 and 75 and have had certain types of colon polyps removed, you may be able to help us build better prediction methods.

Testing a tumor marker to predict colon cancer relapse risk

This study looks at whether a lab test on your tumor can better predict the chance that non-metastatic colon cancer will come back after surgery. Researchers will compare relapse risk using the Immunoscore® test to help guide follow-up and treatment decisions.

Study of avutometinib, defactinib, and cetuximab for advanced colorectal cancer

This trial tests a combination of three drugs for people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if combining these drugs can shrink tumors or slow cancer growth.

Oral drugs and radiation for advanced colorectal cancer after standard therapy

This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.

MASLD risk in breast or colorectal cancer survivors

This study looks at whether breast or colorectal cancer survivors are more likely to develop a liver condition called MASLD (fatty liver disease not caused by alcohol). It uses blood tests, imaging, and possibly an MRI to check liver health.

LGR5-targeted CAR-T for metastatic colorectal cancer

This early-phase study tests an autologous CAR-T cell treatment that is designed to recognize LGR5 on colorectal cancer cells. It aims to shrink metastatic colorectal cancer that has already been treated with up to two prior standard chemotherapy regimens.

Chemo and targeted therapy before surgery for recurrent colorectal cancer

This trial tests a combination of chemotherapy (CapeOX), a targeted drug (bevacizumab), and an immunotherapy (anti-PD1) given before surgery for colorectal cancer that has come back locally (in the same area). The goal is to shrink the tumor and improve surgical outcomes.

Combination therapy for advanced colorectal cancer

This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.

Testing NEO212 for brain tumors and metastases

This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.

Huaier granules to help prevent colorectal cancer coming back

This study tests whether Huaier granules after surgery can lower the chance that colorectal cancer returns or spreads. It is for people who have recently had “radical” (complete) surgery for certain stages of colorectal cancer and are within about 2 months of that surgery.

Study of chemotherapy side effects in older colorectal cancer patients

This study looks at how chemotherapy and immunotherapy affect the body in older adults with colorectal cancer, especially early side effects. It may help researchers understand why some people lose strength and how to better predict and manage treatment toxicity.

Test dual-task walking to improve thinking in colorectal cancer

This study looks at a walking exercise that makes you do two tasks at once (for example, walking while focusing on something) to see if it can improve thinking and memory. It is for people newly diagnosed with early to mid-stage colorectal cancer, and excludes people with other cancers or cancer coming back.

Avapritinib for tumors with specific KIT or PDGFRA changes

This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.

Virtual reality program to reduce stomach-cancer pain

This trial tests whether virtual reality (VR) can improve pain and other day-to-day symptoms in people with certain gastrointestinal cancers. You’d use VR for pain relief while researchers measure how you’re feeling.

New immune vaccine plus nivolumab for liver cancer

This trial studies whether an individualized “neoantigen” cancer vaccine given to immune cells (dendritic cells) plus nivolumab can improve outcomes in people with liver cancer and/or colorectal cancer that has spread only to the liver. It focuses on tumors that can be removed with curative surgery (with or without local ablation) and on people with good enough liver and overall health.

Blood test study to spot early cancer signal and cancer leftovers

This observational study checks whether a blood test (a “cfDNA” test) can detect early signs of cancer or small amounts of cancer left after treatment. It may help doctors use a simple blood sample to improve cancer detection and follow-up.

Targeted cancer drug study for RAS/RAF mutation-positive tumors

This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.

After-surgery blood test–guided therapy for colon cancer liver spread

This Phase 3 trial tests whether an added “maintenance” treatment after liver surgery can help prevent colorectal cancer from coming back. It is only for people whose blood test (ctDNA) still shows signs of cancer after their operation.

ctDNA-guided chemo after liver surgery for colon cancer

This trial checks whether giving chemotherapy after surgery only for people whose blood test (ctDNA) shows no remaining cancer can help prevent the cancer from coming back. It is for people with colon cancer that has spread to the liver who had the tumor fully removed.